 phase high-dos ifosfamid dose carboplatin autolog bone marrow support dose-limit toxic separ phase trial high-dos singl agent ifosfamid carboplatin renal insuffici hepat ototox phase adult ifosfamid single-ag maximum-toler dose mtd dose carboplatin nonhematolog dose-limit toxic maximum-toler dose combin drug mesna uroprotect continu infus day addit day mesna total dose cours autolog bone marrow support subsequ dose level granulocyt day patient dose level autolog bone marrow support dose carboplatin dose level maximum-toler dose level carboplatin renal toxic dose escal patient dose level revers creatinin elev mg/dl median peak mg/dl patient irrevers renal failur addit patient peak creatinin mg/dl transient gross hematuria common combin ifosfamid patient sever somnol confus creatinin complet cr partial respons pr assess patient partial complet respons assess patient advanc refractori sarcoma CR patient germ cell carcinoma carboplatin renal toxic nevertheless carboplatin ifosfamid single-ag maximum-toler dose accept nonhematolog toxic ifosfamid carboplatin attract core combin studi treatment sarcoma germ cell ovarian lung carcinoma